Compare Biogen Inc (BIIB) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs CSX Corporation — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while CSX Corporation trades at $50.1 (market cap $92.55B). The key difference: CSX Corporation is far larger — about 3.1× Biogen Inc's market cap, and CSX Corporation pays a 1.12% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CSX | |
|---|---|---|
Market Cap | $30.13B | $92.55B |
Sector | Health | Industrials |
52-Week High | $216.63 | $53.21 |
52-Week Low | $128.93 | $32.05 |
Enterprise Value | $37.20B | $110.52B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
CSX trades at $50.09, down slightly by 0.06% today, with a neutral technical signal. Recent Q2 2026 earnings beat expectations with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and improved margins. Analyst consensus is bullish with a $52.57 price target, supported by strong cash flow trends and a 58.69% buy rating from coverage.
The outlook is positive due to volume growth and cost controls, but risks include fuel cost pressures and competitive freight markets. With a P/E of 29.05 above industry averages, the stock offers growth potential if earnings momentum continues, though high debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
